文章：

非小细胞肺癌患者经抗PD-1/PD-L1抗体联合化疗后再次接受抗PD-1/PD-L1抗体治疗的预期性多机构观察研究：北日本肺癌研究组（NJLCG）试验1901

Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901

原文发布日期：2 May 2025

DOI: 10.3390/cancers17091551

类型: Article

开放获取: 是

英文摘要：

The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC) [...]

摘要翻译： 

免疫检查点抑制剂（ICIs）的出现彻底改变了非小细胞肺癌（NSCLC）的标准治疗方案。

原文链接：

Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901